Interleukin-10 (IL-10) in Cancer Immunotherapy
DOI:
https://doi.org/10.61173/6a6hm842Keywords:
Interleukin-10 (IL-10), Cancer Immunotherapy, Cytokine, CancerAbstract
Cancer immunotherapy is an essential therapeutic strategy for the treatment of cancer. In cancer immunotherapy, cytokines, such as interleukin-10 (IL-10), have a vital function. IL-10, synthesized by several types of immune cells, has a vital function in controlling immunological responses, such as subsistence T cells and dendritic cells (DCs), as well as other kinds of cells producing other cytokines. In the immune system, suppressing or reducing the growth and harmful effects of specific immune cells is the main role of this component. Pegylated recombinant human IL-10 and other IL-10 inhibitors can reverse the suppressive impact of IL-10, providing possible ways to control immune responses. IL-10 is mainly recognized for its ability to reduce inflammation and regulate the immune system. However, its involvement in cancer is complex and varies depending on the specific circumstances. IL-10-based treatment has had some degree of success in several forms of cancer. Furthermore, IL-10-derived medications have achieved significant advancements in both animal models and clinical studies, including in humans. While the rate of research progress may fluctuate for various types of malignancies, existing records suggest that IL-10-based immunotherapy shows promising potential.
References
[1] Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med, 2020, 217(1): e20190418.
[2] Wang X, Wong K, Ouyang W, Rutz S. Targeting IL-10 Family Cytokines for the Treatment of Human Diseases. Cold Spring Harb Perspect Biol, 2019, 11(2): a028548.
[3] Qi L, Yu H, Zhang Y, Zhao D, Lv P, Zhong Y, Xu Y. IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma. Oncotarget, 2016, 7(44): 71673-71685.
[4] Marcon F, Zuo J, Pearce H, Nicol S, Margielewska-Davies S, Farhat M, Mahon B, Middleton G, Brown R, Roberts KJ, Moss P. NK cells in pancreatic cancer demonstrate impaired cytotoxicity and a regulatory IL-10 phenotype. Oncoimmunology, 2020, 9(1): 1845424.
[5] Naing A, Infante JR, Papadopoulos KP, et al. PEGylated IL- 10 (Pegilodecakin) induces systemic immune activation, CD8+ T cell invigoration, and polyclonal T cell expansion in cancer patients. Cancer Cell, 2018, 34(5): 775–791.e3.
[6] Limei Shen, Jingjing Li, Qi Liu, Wantong Song, Xueqiong Zhang, Karthik Tiruthani, Haiyang Hu, Manisit Das, Tyler Jay Goodwin, Rihe Liu, and Leaf HuangACS Nano. Local Blockade of Interleukin 10 and C-X-C Motif Chemokine Ligand 12 with Nano-Delivery Promotes Antitumor Response in Murine Cancers, 2018, 12(10): 9830-9841.
[7] Ni G, Zhang L, Yang X, Li H, Ma B, Walton S, Wu X, Yuan J, Wang T, Liu X. Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task. Hum Vaccin Immunother, 2020, 16(10): 2328-2332.
[8] Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer, 2020, 1873(1): 188314.
[9] Ahmad Mustafa Shiri, Tao Zhang, Tanja Bedke, Dimitra E. Zazara, Lilan Zhao, Jöran Lücke, Morsal Sabihi, Antonella Fazio, Siwen Zhang, Daniele V.F. Tauriello, Eduard Batlle, Babett Steglich, Jan Kempski, Theodora Agalioti, Mikołaj Nawrocki, Yang Xu, Kristoffer Riecken, Imke Liebold, Leonie Brockmann, Leonie Konczalla, Lidia Bosurgi, Baris Mercanoglu, Philipp Seeger, Natalie Küsters, Panagis M. Lykoudis, Asmus Heumann, Petra C. Arck, Boris Fehse, Philipp Busch, Rainer Grotelüschen, Oliver Mann, Jakob R. Izbicki, Thilo Hackert, Richard A. Flavell, Nicola Gagliani, Anastasios D. Giannou, Samuel Huber, IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction, Journal of Hepatology, 2023, ISSN 0168-8278.
[10] Jessup, J.M., Samara, R., Battle, P. et al. Carcinoembryonic antigen promotes tumor cell survival in liver through an IL-10- dependent pathway. Clin Exp Metastasis, 2005.
[11] Qian Q, Wu C, Chen J, Wang W. Relationship between IL10 and PD-L1 in Liver Hepatocellular Carcinoma Tissue and Cell Lines. Biomed Res Int, 2020, 2020: 8910183.
[12] Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment. Gastroenterology, 2022, 163(2): 386-402. e1.
[13] Feng L, Qi Q, Wang P, Chen H, Chen Z, Meng Z, Liu L. Serum levels of IL-6, IL-8, and IL-10 are indicators of prognosis in pancreatic cancer. J Int Med Res, 2018, 46(12): 5228-5236.
[14] Sideras K, Braat H, Kwekkeboom J, van Eijck CH, Peppelenbosch MP, Sleijfer S, Bruno M. Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies. Cancer Treat Rev, 2014, 40(4): 513-22.
[15] Tannir NM, Papadopoulos KP, Wong DJ, Aljumaily R, Hung A, Afable M, Kim JS, Ferry D, Drakaki A, Bendell J, Naing A. Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer, 2021, 149(2): 403-408.
[16] Naing A, Infante JR, Papadopoulos KP, Chan IH, Shen C, Ratti NP, Rojo B, Autio KA, Wong DJ, Patel MR, Ott PA, Falchook GS, Pant S, Hung A, Pekarek KL, Wu V, Adamow M, McCauley S, Mumm JB, Wong P, Van Vlasselaer P, Leveque J, Tannir NM, Oft M. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer Cell, 2018, 34(5): 775-791.e3.
[17] Chang WS, Liao CH, Tsai CW, Hu PS, Wu HC, Hsu SW, Ji HX, Hsiao CL, Bau DT. The Role of IL-10 Promoter Polymorphisms in Renal Cell Carcinoma. Anticancer Res, 2016, 36(5): 2205-9.
[18] Davidsson S, Huotilainen S, Carlsson J, Sundqvist P. Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients. Diagnostics (Basel), 2022, 12(2): 336.
[19] Bobos M. Histopathologic classification and prognostic factors of melanoma: a 2021 update. Ital J Dermatol Venereol, 2021, 156:300-21.
[20] Ralli M, Botticelli A, Visconti IC, Angeletti D, Fiore M, Marchetti P, Lambiase A, de Vincentiis M, Greco A. Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res, 2020, 2020: 9235638.
[21] Michielon E, López González M, Burm JLA, Waaijman T, Jordanova ES, de Gruijl TD, Gibbs S. Micro-environmental cross-talk in an organotypic human melanoma-in-skin model directs M2-like monocyte differentiation via IL-10. Cancer Immunol Immunother, 2020, 69(11): 2319-2331.
[22] Sawant DV, Yano H, Chikina M, Zhang Q, Liao M, Liu C, Callahan DJ, Sun Z, Sun T, Tabib T, Pennathur A, Corry DB, Luketich JD, Lafyatis R, Chen W, Poholek AC, Bruno TC, Workman CJ, Vignali DAA. Adaptive plasticity of IL- 10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion. Nat Immunol, 2019, 20(6): 724-735.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
